布他卡摩在新入院的慢性精神分裂症患者中的应用:改良的固定剂量剂量范围设计。

Diseases of the nervous system Pub Date : 1977-11-01
M L Clark, J P Costiloe, F Wood, A Paredes, F G Fulkerson
{"title":"布他卡摩在新入院的慢性精神分裂症患者中的应用:改良的固定剂量剂量范围设计。","authors":"M L Clark,&nbsp;J P Costiloe,&nbsp;F Wood,&nbsp;A Paredes,&nbsp;F G Fulkerson","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>In a double-blind placebo controlled study of newly admitted chronic schizophrenics, an attempt was made to further evaluate the safety, acceptability, and effectiveness of BT in doses of 10, 20, and 40 mg. Significant dose related responses occurred on several behavioral variables by the first week of treatment. Maximum clinical response appeared to be at the 20-40 mg. dose level. Extrapyramidal signs occurred at all doses, but with greater severity at higher doses. Excessive daytime drowsiness occurred in all groups but with longer duration and greater intensity in the 20 mg. group. Rebound insomnia occurred after the abrupt withdrawal of BT at all dose levels suggesting the desirability of further study of its hypnotic properties.</p>","PeriodicalId":75808,"journal":{"name":"Diseases of the nervous system","volume":"38 11","pages":"943-7"},"PeriodicalIF":0.0000,"publicationDate":"1977-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Butaclamol in newly admitted chronic schizophrenic patients: a modified fixed-dose dose-range design.\",\"authors\":\"M L Clark,&nbsp;J P Costiloe,&nbsp;F Wood,&nbsp;A Paredes,&nbsp;F G Fulkerson\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In a double-blind placebo controlled study of newly admitted chronic schizophrenics, an attempt was made to further evaluate the safety, acceptability, and effectiveness of BT in doses of 10, 20, and 40 mg. Significant dose related responses occurred on several behavioral variables by the first week of treatment. Maximum clinical response appeared to be at the 20-40 mg. dose level. Extrapyramidal signs occurred at all doses, but with greater severity at higher doses. Excessive daytime drowsiness occurred in all groups but with longer duration and greater intensity in the 20 mg. group. Rebound insomnia occurred after the abrupt withdrawal of BT at all dose levels suggesting the desirability of further study of its hypnotic properties.</p>\",\"PeriodicalId\":75808,\"journal\":{\"name\":\"Diseases of the nervous system\",\"volume\":\"38 11\",\"pages\":\"943-7\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1977-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diseases of the nervous system\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diseases of the nervous system","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在一项针对新入院的慢性精神分裂症患者的双盲安慰剂对照研究中,试图进一步评估BT在10、20和40 mg剂量下的安全性、可接受性和有效性。在治疗的第一周,几个行为变量出现了显著的剂量相关反应。最大的临床反应似乎是在20-40毫克。剂量水平。所有剂量均出现锥体外系症状,但剂量越高,症状越严重。所有组均出现白天嗜睡,但20 mg组持续时间更长,强度更大。组。在所有剂量水平的BT突然停药后都会出现反弹性失眠,提示需要进一步研究其催眠特性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Butaclamol in newly admitted chronic schizophrenic patients: a modified fixed-dose dose-range design.

In a double-blind placebo controlled study of newly admitted chronic schizophrenics, an attempt was made to further evaluate the safety, acceptability, and effectiveness of BT in doses of 10, 20, and 40 mg. Significant dose related responses occurred on several behavioral variables by the first week of treatment. Maximum clinical response appeared to be at the 20-40 mg. dose level. Extrapyramidal signs occurred at all doses, but with greater severity at higher doses. Excessive daytime drowsiness occurred in all groups but with longer duration and greater intensity in the 20 mg. group. Rebound insomnia occurred after the abrupt withdrawal of BT at all dose levels suggesting the desirability of further study of its hypnotic properties.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信